Company news

Mayne Pharma Group Ltd. news in 2016

Mayne Pharma Group Ltd.'s news releases, calls and decks from 2016, newest first.

View company

Update on Status of DOJ Investigation

December 15, 2016

S&P DJ Indices Announces March Quarterly Rebalance

November 7, 2016

MYX launches generic MS Contin (morphine sulfate) tablets

November 2, 2016

IDT: 1st generic proprietary prod shipped to US, temozolomide

November 1, 2016

MYX launches generic Entocort EC (Budesonide) capsules

October 26, 2016

Appendix 4E, Directors Report and Financial Statements

August 25, 2016

MYX announces acquisition of US foam dermatology assets

August 17, 2016

MYX announces settlement from patent infringement case

July 29, 2016

Completion institutional entitlement offer and placement

June 29, 2016

MYX announces acquisition of US generic product portfolio

June 27, 2016

MYX receives first generic approval of Tikosyn capsules

June 6, 2016

Mayne Pharma receives FDA approval for Doryx MPC tablets

May 23, 2016

2015 Appendix 4E & Annual Report

February 11, 2016

US Sales of Doryx Update

February 10, 2016

US Oxycodone franchise restructure and Doryx re-launch

February 10, 2016

US Court decides on Doryx 161 Patent

February 10, 2016

Successful Phase II SUBACAP trial

February 10, 2016

Successful EU SUBA Clinical Study

February 10, 2016

SUBACAP Update

February 10, 2016

Singapore Distribution Agreement Signed

February 10, 2016

Retail Offer Booklet

February 10, 2016

Preliminary Final Report and Maiden Dividend

February 10, 2016

Pfizer withdraws US Tikosyn Litigation against Mayne Pharma

February 10, 2016

New equity investment in Hedgepath Pharmaceuticals

February 10, 2016

MYX appoints scott richards as CEO

February 10, 2016

MYX announces US agreement for Itraconazole in Cancer

February 10, 2016

Media Speculation

February 10, 2016

Mayne Pharma successfully completes US$125m debt financing

February 10, 2016

Mayne Pharma Signs European SUBACAP Distribution Agreements

February 10, 2016

Mayne Pharma results and product update

February 10, 2016

Mayne Pharma recipient of A$4m Government Grant

February 10, 2016

Mayne Pharma out-licenses IP to Hedgepath Pharmaceuticals

February 10, 2016

Mayne Pharma Market Update

February 10, 2016

Mayne Pharma Launches Generic Doryx

February 10, 2016

Mayne Pharma announces US Paragraph IV Challenge

February 10, 2016

Mayne Pharma Announces the Acquisition of Metrics, Inc.

February 10, 2016

Mayne Pharma announces the acquisition of Kapanol

February 10, 2016

Mayne Pharma announces SUBACAP approvable

February 10, 2016

Mayne Pharma announces in-licensing agreement

February 10, 2016

Mayne Pharma announces acquisition of LORCET & ESGIC

February 10, 2016

Mayne Pharma announces acquisition of Libertas

February 10, 2016

Mayne Pharma announces acquisition of Doryx

February 10, 2016

Mayne announces strategic investment in US facilities

February 10, 2016

Half Year Results and Accounts

February 10, 2016

Future Cash Flow Reporting

February 10, 2016

FDA Approval Of New Dual-Scored 150mg Doryx Tablet

February 10, 2016

FDA Approval of New 200mg Doryx Tablet

February 10, 2016

Doryx Generic Update

February 10, 2016

Director resignation and management update

February 10, 2016

Completion of US Phase II Study Recruitment

February 10, 2016

Older news releases →

Decks in 2016